This breakthrough unlocks the potential to accelerate time to clinic by over 50% and increase probability of success in the clinic
Creating antibodies in silico with generative AI represents a major industry breakthrough on the path to fully de novo antibody design and Absci’s vision to deliver breakthrough therapeutics at the click of a button, for everyone.
Historically, biologic drug discovery is risky, time-consuming, and expensive, with a >90% failure rate. It takes an average of 10 years and >
“It’s a slow, arduous process to bring just one safe, effective drug to the market. I have overseen the development of over ten drugs to approval throughout my career, and know the labor and dedication required for the small chance of creating a therapeutic that can improve lives,” said
Absci’s breakthrough demonstrates generative AI as an alternative to traditional biologic drug discovery, potentially unlocking treatments for traditionally “undruggable” diseases and improving therapeutic possibilities for many others.
Scalable biological data has been one of the biggest barriers to applying generative AI to biologic drug discovery.
“Despite the technological breakthroughs of the last decade, the process of drug discovery has remained relatively archaic. Our success in creating brand new antibodies on a computer unlocks the potential to create transformative therapies at a click of a button for patients,” said
The achievement is also the first example of a generative AI engine designing new therapeutic antibodies by designing the heavy chain complementarity determining region 3 (HCDR3) from scratch, where the computational design has been wet-lab validated to bind to the intended targets. HCDR3 is a critical region for antibodies to bind to their targets and enable their therapeutic potential.
The bioRxiv preprint manuscript with technical details of the achievement can be found here.
About
Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Our vision is to deliver breakthrough therapeutics at the click of a button, for everyone.
Absci’s headquarters is in
Availability of Other Information about
Investors and others should note that we routinely communicate with investors and the public using our website (www.absci.com) and our investor relations website (investors.absci.com), including without limitation, through the posting of investor presentations,
Absci Forward-Looking Statements
Certain statements in this press release that are not historical facts are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements containing the words “will,” “pursues,” “anticipates,” “plans,” “believes,” “forecast,” “estimates,” “extends,” “expects,” and “intends,” or similar expressions. We intend these forward-looking statements, including statements regarding our expectations regarding business operations, financial performance and results of operations, including our expectations and guidance regarding cash and cash equivalents, short-term investments and restricted cash, our projected cash usage, needs and runway, our expectations for the count of new Active Programs, technology development efforts and the application of those efforts, including acceleration of drug development timelines, advancements toward in silico drug design, drug discovery and development activities, internal research and publication efforts, and research and technology development collaboration efforts, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and we make this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved, and, furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks and uncertainties relating to our ability to effectively collaborate on research, drug discovery and development activities with our partners or potential partners; along with those risks set forth in our most recent periodic report filed with the
Investor Contact
investors@absci.com
Media Contact
press@absci.com
![](https://ml.globenewswire.com/media/MjVlYjg2NTctZmM0ZC00ODg2LWE5ZWMtMDA0YWRiMWE3N2U2LTEyMjE2MzM=/tiny/ABSCI-Corporation.png)
2023 GlobeNewswire, Inc., source